Ramucirumab: A novel antiangiogenic agent

Roopma Wadhwa; Takashi Taketa; Kazuki Sudo; Mariela Blum-Murphy; Jaffer A. Ajani

doi:10.2217/fon.13.68

Ramucirumab: A novel antiangiogenic agent

Roopma Wadhwa, Takashi Taketa, Kazuki Sudo, Mariela Blum-Murphy, Jaffer A. Ajani

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.

Original language	English (US)
Pages (from-to)	789-795
Number of pages	7
Journal	Future Oncology
Volume	9
Issue number	6
DOIs	https://doi.org/10.2217/fon.13.68
State	Published - Jun 2013

Keywords

IMC-1121B
VEGF
VEGFR2
angiogenesis
antiangiogenesis agent
ramucirumab

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.13.68

Cite this

@article{d175e20c26354917bf8b93787b9774d6,

title = "Ramucirumab: A novel antiangiogenic agent",

abstract = "Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.",

keywords = "IMC-1121B, VEGF, VEGFR2, angiogenesis, antiangiogenesis agent, ramucirumab",

author = "Roopma Wadhwa and Takashi Taketa and Kazuki Sudo and Mariela Blum-Murphy and Ajani, {Jaffer A.}",

year = "2013",

month = jun,

doi = "10.2217/fon.13.68",

language = "English (US)",

volume = "9",

pages = "789--795",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Ramucirumab

T2 - A novel antiangiogenic agent

AU - Wadhwa, Roopma

AU - Taketa, Takashi

AU - Sudo, Kazuki

AU - Blum-Murphy, Mariela

AU - Ajani, Jaffer A.

PY - 2013/6

Y1 - 2013/6

N2 - Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.

AB - Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.

KW - IMC-1121B

KW - VEGF

KW - VEGFR2

KW - angiogenesis

KW - antiangiogenesis agent

KW - ramucirumab

UR - http://www.scopus.com/inward/record.url?scp=84878492693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878492693&partnerID=8YFLogxK

U2 - 10.2217/fon.13.68

DO - 10.2217/fon.13.68

M3 - Article

C2 - 23718298

AN - SCOPUS:84878492693

SN - 1479-6694

VL - 9

SP - 789

EP - 795

JO - Future Oncology

JF - Future Oncology

IS - 6

ER -

Ramucirumab: A novel antiangiogenic agent

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this